睿知中国医院研究地图
候选清单

正在招募肺癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

ClinicalTrials.gov 上登记的一项肺癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学肿瘤医院Peking University Cancer Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06869239,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. 2. Histologically or cytologically confirmed limited-stage small cell lung cancer (LS-SCLC) (AJCC, 8th edition);

    入选标准第 2 条

    Total bilirubin (TBIL) ≤1.5 ULN; Note: Patients diagnosed with Gilbert's syndrome (persistent or recurrent hyperbilirubinemia [mainly unconjugated bilirubin] without evidence of hemolysis or liver pathology) after consultation with their physician can be allowed;

    入选标准第 17 条

  3. 2. Extensive-stage SCLC;

    排除标准第 2 条

  4. 3. No more than 2 cycles of chemotherapy or no previous systemic therapy;

    入选标准第 3 条

    4. Treatment with immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 14 days prior to the first dose of PD-L1 inhibitor, except for intranasal and inhaled corticosteroids or low-dose systemic steroids (i.e., ≤10 mg/day prednisolone or equivalent);

    排除标准第 4 条

    Malignancy that has been treated with curative intent, with no known active disease for ≥5 years prior to the first dose of the study treatment, and with a low potential risk of recurrence;

    排除标准第 14 条

    15. Treatment with any other investigational agent with therapeutic intent within 4 weeks prior to the first dose of the study treatment;

    排除标准第 19 条

  5. 4. ECOG PS 0-1;

    入选标准第 4 条

  6. Hemoglobin (HGB) ≥90 g/L;

    入选标准第 10 条

    Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L;

    入选标准第 11 条

    Platelet count (PLT) ≥ 100 x 10\^9/L;

    入选标准第 12 条

    White blood cell count (WBC) ≥ 3.0 x 10\^9/L;

    入选标准第 13 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN;

    入选标准第 16 条

    Creatinine ≤ 1.5 ULN;

    入选标准第 18 条

  7. 5. Measurable disease, as defined by RECIST v1.1 (tumor lesions long axis≥10mm, lymph nodes short axis ≥15mm);

    入选标准第 5 条

  8. 7. Active or history of autoimmune disease or immune deficiency (including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism);

    排除标准第 7 条

    10. Malignancies other than LS-SCLC, with the following exceptions:

    排除标准第 12 条

    11. Human immunodeficiency virus (HIV) infection or known to have acquired immunodeficiency syndrome (AIDS);

    排除标准第 15 条

    14. Active tuberculosis, hepatitis B (HBV-DNA ≥ 500 IU/ml), hepatitis C (positive hepatitis C antibody and HCV-RNA above the lower limit of detection of the assay), or co-infection with both hepatitis B and C;

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06869239,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. Age 18-75 years, male or female;
  2. 2. Histologically or cytologically confirmed limited-stage small cell lung cancer (LS-SCLC) (AJCC, 8th edition);
  3. 3. No more than 2 cycles of chemotherapy or no previous systemic therapy;
  4. 4. ECOG PS 0-1;
  5. 5. Measurable disease, as defined by RECIST v1.1 (tumor lesions long axis≥10mm, lymph nodes short axis ≥15mm);
  6. 6. Life expectancy ≥3 months;
  7. 7. Adequate pulmonary function;
  8. 8. Adequate hematologic and end-organ function, defined by the following criteria:
  9. Hematology
  10. Hemoglobin (HGB) ≥90 g/L;
  11. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L;
  12. Platelet count (PLT) ≥ 100 x 10\^9/L;
  13. White blood cell count (WBC) ≥ 3.0 x 10\^9/L;
  14. Serum chemistry
  15. Serum albumin (ALB) ≥ 30 g/L;
  16. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN;
  17. Total bilirubin (TBIL) ≤1.5 ULN; Note: Patients diagnosed with Gilbert's syndrome (persistent or recurrent hyperbilirubinemia [mainly unconjugated bilirubin] without evidence of hemolysis or liver pathology) after consultation with their physician can be allowed;
  18. Creatinine ≤ 1.5 ULN;
  19. 9. Women of childbearing age must have taken reliable contraceptive measures or undergone a negative pregnancy test (serum or urine) within 7 days prior to enrollment. Both men and women of childbearing age must agree to maintain adequate contraceptive measures throughout the study and for 6 months following the completion of treatment;
  20. 10. Patients must voluntarily participate in this study, sign the informed consent form, demonstrate good compliance, and actively cooperate with follow-up procedures.

排除标准:Exclusion Criteria:

  1. 1. Histological mixture of SCLC and NSCLC components;
  2. 2. Extensive-stage SCLC;
  3. 3. Patients with a history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, or those planned for transplantation;
  4. 4. Treatment with immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 14 days prior to the first dose of PD-L1 inhibitor, except for intranasal and inhaled corticosteroids or low-dose systemic steroids (i.e., ≤10 mg/day prednisolone or equivalent);
  5. 5. History of hypersensitivity to etoposide, cisplatin, PD-L1 antibody, or excipients in the formulation; or history of severe allergic reactions to other monoclonal antibodies;
  6. 6. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment;
  7. 7. Active or history of autoimmune disease or immune deficiency (including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism);
  8. Patients with vitiligo or alopecia are eligible for this study;
  9. Patients with stable hypothyroidism undergoing hormone replacement therapy (e.g., Hashimoto's syndrome) are eligible for this study;
  10. 8. Poorly controlled asthma despite systemic treatment, such as bronchodilators; Note: Patients with complete remission of asthma during childhood and no need for any intervention in adulthood can be allowed;
  11. 9. Urinalysis shows proteinuria ≥ ++ or confirmed 24-hour urine protein ≥ 1.0g;
  12. 10. Malignancies other than LS-SCLC, with the following exceptions:
  13. Adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix;
  14. Malignancy that has been treated with curative intent, with no known active disease for ≥5 years prior to the first dose of the study treatment, and with a low potential risk of recurrence;
  15. 11. Human immunodeficiency virus (HIV) infection or known to have acquired immunodeficiency syndrome (AIDS);
  16. 12. Significant cardiovascular disease within 6 months prior to enrollment, such as myocardial infarction, severe/unstable angina, New York Heart Association cardiac disease (class II or greater), poorly controlled arrhythmias (including QTcF interval >450 ms for males and >470 ms for females, with QTcF interval calculated using the Fridericia formula), and symptomatic congestive heart failure;
  17. 13. Severe infections within 4 weeks prior to first dose of study treatment, including but not limited to infections requiring intravenous antibiotics, antifungal, or antiviral agents , or unexplained fever ≥38.5°C occurring during the screening period or before the first dose of the study treatment;
  18. 14. Active tuberculosis, hepatitis B (HBV-DNA ≥ 500 IU/ml), hepatitis C (positive hepatitis C antibody and HCV-RNA above the lower limit of detection of the assay), or co-infection with both hepatitis B and C;
  19. 15. Treatment with any other investigational agent with therapeutic intent within 4 weeks prior to the first dose of the study treatment;
  20. 16. History of abuse of psychotropic drugs or drug addiction;
  21. 17. Patients with other severe physical or mental illnesses or abnormal laboratory test results that may increase the risk of participating in the study, or interfere with the study results, as well as those whom the investigator deems unsuitable for participation in the study for other reasons.

引自 ClinicalTrials.gov, NCT06869239, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06869239,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06869239